Auauniversity

CME Available: https://auau.auanet.org/node/35793 Course Director: Amy Krambeck, MD Faculty: Dean Elterman, MD; Steven Kaplan, MD; Lori Lerner, MD ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Cook Medical Olympus Corporation of the Americas LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Identify the role of diagnostic testing in making the accurate diagnosis of mLUTS using the new benign BPH guidelines. 2. Recognize the various agents available to treat mLUTS. 3. Describe the indications for the various ablative BPH procedures. 4. Illustrate the impact of current therapeutic strategies on both voiding and sexual dysfunction. 5. Identify the role of the AUA guidelines for BPH for the surgical and medical management of BPH.

CME Available: https://auau.auanet.org/node/35710 Course Director: Stephen A. Boorjian, MD Faculty: Leonard G. Gomella, MD, FACS; David F. Jarrard, MD; Alicia K. Morgans, MD, MPH ACKNOWLEDGMENTS: This educational activity is supported by independent education grants from: Astellas AstraZeneca Merck & Co., Inc. Pfizer, Inc. At the conclusion of the activity, participants will be able to: LEARNING OBJECTIVES: 1. Describe recent developments in the medical management of advanced prostate cancer. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 2. Discuss clinical investigations in the treatment of advanced prostate cancer. 3. Analyze the risks and benefits of treatment for advanced prostate cancer. 4. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

CME Available: https://auau.auanet.org/node/35599 Course Director: David A. Ginsberg, MD Faculty: Anne P. Cameron, MD, FRCSC, FPMRS; Sara M. Lenherr, MD, MS, FPRMS, Eric Rovner, MD; Eric Rovner, MD ACKNOWLEDGEMENTS This educational activity is supported by an independent educational grant from: Urovant LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies. 2. Describe the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 3. Discuss optimal use of third line therapies in order to maximize clinical benefit. 4. Counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB.

Host: Jay D. Raman, MD, FACS Guest: John P. Mulhall, MD Outline: Segment 1: The 4 R's of Scientific Publishing Segment 2: Plagiarism Segment 3: Authorship Issues Segment 4: Conflict of Interest Segment 5: IRB (IACUC)Issues Segment 6: Fabrication/Falsification Segment 7: Reviewer Malpractice Segment 8: Predatory Journals For more information, please visit: AUAnet.org/University

Publishing Ethics Co-Host: John P. Mulhall, MD Outline: Segment 1: The 4 R's of scientific publishing Segment 2: Plagiarism Segment 3: Authorship issues Segment 4: Conflict of interest Segment 5: IRB (IACUC) issues Segment 6: Fabrication/Falsification Segment 7: Reviewer malpractice Segment 8: Predatory journals

Adolescent and Young Adult (AYA) Oncology Focusing on Translocation RCC Co-Host: Nick G. Cost, MD Outline: Topic 1: Adolescents with cancer are different from both children and older adults with cancer Topic 2: Differences in biology Topic 3: Differences in clinical behavior Topic 4: Specific clinical trial options Topic 5: Summary – “Now what? What should I do the next time I see an AYA with kidney cancer?”

CME Available: https://auau.auanet.org/node/35405 Moderator: Todd Morgan, MD Panelists: Maria Carlo, MD; Elisabeth Heath, MD, FACP; Brian Helfand, MD At the conclusion of this activity, participants will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients, explain how to counsel patients about genetic testing, and how to order and interpret these tests. 2. Explain how mutations in DNA damage repair genes can lead to the development of aggressive prostate cancer and the implications for treatment decisions. 3. Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition for cancer treatment. 4. Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial. ACKNOWLEDGEMENTS Support provided by independent educational grants from: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Af

New Minimally Invasive BPH Treatment Options Co-Host: John V. Kaspar, MD Acknowledgements: This podcast was funded by and developed in collaboration with Olympus Corporation. Outline: Segment 1: BPH patient needs Segment 2: AUA Guideline changes Segment 3: MIST procedures and patient selection Segment 4: Site of service for MIST treatment Segment 5: Anatomical considerations between therapies

CME Available: https://auau.auanet.org/node/35401 Learning Objectives: After participating in this educational series, participants will be able to: 1. List advanced prostate cancer disease states (mHSPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice. 2. Identify available approved therapies and outcomes for each of these disease states: MHSPC, M0 CRPC, M1 CRPC. 3. Demonstrate the appropriate indications, unique mechanisms of action and side effects of new and existing androgen axis agents, immunotherapies, chemotherapeutic agents and bone targeted therapies. 4. Explain the sequencing of available therapies, as well as identifying adverse events that might occur when considering combination therapy. 5. Review the evidence and outcomes on androgen deprivation treatment alone and in combination as outlined in the newly released Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline. Acknowledgements: Support provided by independent educational grants from: AstraZeneca Janssen B

Host: Jay D. Raman, MD, FACS Guest: David B. Bock, MD, FACS Outline: Segment 1: Need for Office Sedation Segment 2: Types of procedures for which sedation can be utilized in the office Segment 3: Types of Anesthesia Segment 4: Office Readiness Segment 5: Implementation For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University

Host: Jay D. Raman, MD, FACS Guest: Badar M. Mian, MD, FACS Outline: Segment 1: What are the main issues with transrectal biopsy? Segment 2: Proposed advantages of transperineal biopsy Segment 3: Some of the difference between the two techniques Segment 4: Ongoing RCTs Segment 5: Lessons learned during our RCT For more information, please visit: AUAnet.org/University

Presenter: Cora N. Sternberg, M.D.

Presenter: Rafael E. Carrion, M.D.

Moderator: Samir S. Taneja, MD Panelists: Simpa Salami, MBBS, MPH Edouard Trabulsi, MD Brian Shuch, MD Cheryl T. Lee, MD

AUA2021 State-Of-The-Art Lecture: Robotic Ureteroscopy by AUAUniversity

AUA2021 Panel Discussion: Artificial Intelligence Applications In Urology by AUAUniversity

Speaker: Nitya Abraham, MD

AUA2021 Panel Discussion: COVID And Sexual Medicine by AUAUniversity

AUA2021 John Duckett Memorial Lecture: Nephron Sparing Surgery In The Management Of Wilms Tumor by AUAUniversity

AUA2021 Journal Of Urology Lecture - The Promises And Pitfalls Of Large Database Studies by AUAUniversity